Atossa Therapeutics (ATOS) News Today $0.73 -0.01 (-0.73%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Atossa Therapeutics secures new patent for breast cancer treatmentApril 24 at 9:53 PM | uk.investing.comPRISM Mid-Day Movers: Board Shakeups and Biotech Financings Drive Investor FocusApril 23 at 3:15 PM | theglobeandmail.comAtossa Therapeutics announces issuance of U.S. patentApril 23 at 10:13 AM | markets.businessinsider.comAtossa Therapeutics (NASDAQ:ATOS) Given New $7.25 Price Target at Ascendiant Capital MarketsAscendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a "buy" rating in a report on Monday.April 23 at 8:11 AM | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.25 at Ascendiant Capital MarketsApril 23 at 2:01 AM | americanbankingnews.comAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen PortfolioApril 22 at 8:45 AM | globenewswire.comNona Biosciences Inks Research Partnership With Atossa Therapeutics For Next-gen Breast Cancer DrugsApril 12, 2025 | nasdaq.comAtossa Therapeutics and Nona Biosciences partner in breast cancer antibodiesApril 11, 2025 | markets.businessinsider.comNona Biosciences, Atossa Partner on Next-Gen Breast Cancer Antibody TherapiesApril 11, 2025 | msn.comNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast CancerApril 10, 2025 | prnewswire.comAtossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on MondayAtossa Therapeutics (NASDAQ:ATOS) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.March 31, 2025 | marketbeat.comQ1 EPS Forecast for Atossa Therapeutics Boosted by AnalystAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for Atossa Therapeutics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings oMarch 29, 2025 | marketbeat.comAtossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical ProgressMarch 28, 2025 | tipranks.comAtossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.March 27, 2025 | marketbeat.comAtossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comAtossa Therapeutics reports Q4 EPS (20c), consensus (22c)March 27, 2025 | markets.businessinsider.comQ4 2024 Atossa Therapeutics Inc Earnings CallMarch 26, 2025 | uk.finance.yahoo.comWe Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business GrowthMarch 26, 2025 | finance.yahoo.comAtossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.March 26, 2025 | marketbeat.comAtossa Therapeutics Reports 2024 Financial Results and UpdatesMarch 26, 2025 | tipranks.comAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | markets.businessinsider.comAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comAtossa Therapeutics (ATOS) to Release Earnings on TuesdayAtossa Therapeutics (NASDAQ:ATOS) will be releasing earnings on Tuesday, March 25, Financial Modeling Prep reports.March 22, 2025 | marketbeat.comAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDoes Sugar Feed Cancer? Here’s What the Latest Science SaysMarch 11, 2025 | yahoo.comAtossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifenMarch 11, 2025 | markets.businessinsider.comAtossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional IndicationsMarch 11, 2025 | globenewswire.comAtossa Therapeutics faces Nasdaq delisting over bid priceFebruary 26, 2025 | investing.comSen. Roger Marshall introduces bill to ban federal grants for ‘dangerous’ gain-of-function researchFebruary 26, 2025 | msn.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Significant Growth in Short InterestAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 9,250,000 shares, an increase of 5.8% from the January 15th total of 8,740,000 shares. Based on an average daily volume of 876,500 shares, the days-to-cover ratio is presently 10.6 days.February 17, 2025 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving Average - Here's WhyAtossa Therapeutics (NASDAQ:ATOS) Shares Pass Below 200-Day Moving Average - Here's WhyFebruary 11, 2025 | marketbeat.comAtossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer CareFebruary 5, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for ATOS FY2029 Earnings?Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Atossa Therapeutics in a research report issued to clients and investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar expects that the coFebruary 4, 2025 | marketbeat.comEquities Analysts Set Expectations for ATOS FY2029 EarningsAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.14) per share foFebruary 3, 2025 | marketbeat.comAtossa Genetics stock hits 52-week low at $0.75January 30, 2025 | msn.comAtossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy RatingJanuary 30, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Atossa Therapeutics (NASDAQ:ATOS)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday.January 30, 2025 | marketbeat.comAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591January 30, 2025 | finance.yahoo.comAtossa Therapeutics faces patent setback, continues developmentJanuary 30, 2025 | msn.comAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.January 30, 2025 | globenewswire.comAtossa Therapeutics reports progress in breast cancer treatmentsJanuary 23, 2025 | msn.comAtossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025January 23, 2025 | globenewswire.comSeattle Doctor: Quit Drinking NowJanuary 7, 2025 | msn.comAtossa Therapeutics ‘applauds’ Surgeon General’s advisory on alcoholJanuary 7, 2025 | markets.businessinsider.comAtossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast CancerJanuary 6, 2025 | markets.businessinsider.comCapricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy RatingJanuary 4, 2025 | markets.businessinsider.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short InterestAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a drop of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily volume of 705,500 shares, the short-interest ratio is currently 11.6 days.December 28, 2024 | marketbeat.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Down 6.8% in NovemberAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 11,600,000 shares, a decline of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is presently 18.5 days.December 16, 2024 | marketbeat.comAtossa Therapeutics: Promising Clinical Results Reinforce Buy Rating with Z-endoxifen AdvancementsDecember 12, 2024 | markets.businessinsider.com Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.560.72▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼92▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OLMA News BNTC News CMPS News TKNO News ALLO News TRDA News ARCT News TSHA News HRTX News ATYR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATOS Stock Free ATOS Stock Alerts